• Biochemical markers of placenta growth in multiple pregnancy and its predictive value

Biochemical markers of placenta growth in multiple pregnancy and its predictive value

HEALTH OF WOMAN. 2018.2(128):65–68; doi 10.15574/HW.2018.128.65

Tkachenko A. V.
Shupyk National Medical Academy of Postgraduate Education, Kiev

The objective: estimation of the predictive value of determining the level of growth factor of the placenta (PlGF) and its probable role in the occurrence of the most common gestational complications in multiple pregnancy.
Materials and methods. Level of serum placental growth factor (PlGF) was studied in 64 pregnant women with multiple pregnancy between 16 to 22 weeks of gestation to estimate the predictive significance of this indicator for the development of gestational complications. A control group consisted of 20 pregnant women with uncomplicated singleton pregnancy.
Results. The serum PlGF level in pregnant women with twins in cases of premature birth, placental insufficiency, and preeclampsia was significantly lower, compared to that in women with singleton pregnancy (<154.23±16.2; <252.14±23.4 and <315.56±25.2 pg/ml, respectively versus 434.3±14.2 pg/ml), so was confirmed as unfavorable biochemical marker for the further development of gestational complications in such group of patients.
Conclusion. The early and stepwise prescription of pharmacotherapeutic correction, which includes low molecular weight heparins, low doses acetylsalicylic acid and angioprotectors, jointly with sanation and treatment of the genital tract inflammation, could prolong pregnancy, decrease the frequency and severity of most common complications and improve the perinatal outcomes in twins.
Key words: multiple pregnancy, placental growth factor, prevention of preterm delivery, preeclampsia, placental insufficiency.

REFERENCES

1. Abramchenko VV, Kiselev AG, Orlova OO. 2004. Vedenie beremennosti i rodov vyisokogo riska. M, MIA:400.

2. Burlev VA, Zaydieva ZS, Tyutyunik VL. 1999. Rol faktorov rosta v razvitii platsentarnoy nedostatochnosti. Probl. reprod. 6:7–12.

3. Gavrilenko TI, Ryizhkova NA, Parhomenko AN. 2011. Sosudistyiy endotelialnyiy faktor rosta v klinike vnutrennih zabolevaniy i ego patogeneticheskoe znachenie. Ukr. kardIol. zhurn. 4:87–95.

4. Kudinova EI, Botasheva TL, Orlov AV, Frolov AA, Gimbut VS. 2015. Osobennosti funktsionirovaniya sintsitiotrofoblasta i sistemyi sosudisto-endotelialnyih faktorov rosta pri zaderzhke rosta ploda v pervom i vo vtorom trimestrah beremennosti. Sovremennyie problemyi nauki i obrazovaniya 4.

5. Kulakov VI, Murashko LM. 2002. Prezhdevremennyie rodyi. M, Meditsina:176.

6. Radzinskiy VE, Stolko PYa. 2001. Biohimiya platsentarnoy nedostatochnosti. M, RUDN:273.

7. Sidelnikova VM. 2002. Privyichnaya poterya beremennosti. M, Triada-X:304.

8. Stepanova OI, Furaeva IP, Sokolov DI. 2012. Vliyanie faktorov, sekretiruemyih tkanyu platsentyi, na proliferativnuyu aktivnost endotelialnyih kletok linii EA.hy926. Zhurnal akusherstva i zhenskih bolezney LXI; 5: 80–85.

9. Scherbina NA, Makarenko MV. 2014. Kliniko-morfologicheskie aspektyi razvitiya sindroma zaderzhki rosta ploda. Eksperimentalna і klinschna meditsina 3:143–147.

10. Elzhorukaeva ZhA, Linde VA, Lyisenko AA, Kudinova EI, Martyinenko EA, Grigoryants AA. 2015. Novyiy vzglyad na problemu razvitiya platsentarnoy nedostatochnosti. Sovremennyie problemyi nauki i obrazovaniya 1.

11. Eatman D, Layas MF, Bayorh MA. 2010. Eplerenon suppresses salt* induced vascular endothelial growth factor expression in kidney. Kidney Blood Press. Res. 33:167–173. https://doi.org/10.1159/000316700; PMid:20571278 PMCid:PMC2914374

12. Louise C Kenny, Michael A Black, Lucilla Poston. 2014. Early Pregnancy Prediction of Preeclampsia in Nulliparous Women, Combining Clinical Risk and Biomarkers The Screening for Pregnancy Endpoints (SCOPE) International Cohort Study. Hypertension: 644–652.

13. Santiago Garcia-Tizon Larroca, Ahmet Tayyar, Leona C. Poon. 2014. Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30–33 weeks’ gestation. Fetal Diagn. & Ther.: 36

14. Vivienne C. Ho and Guo-Hua Fong. 2015. Vasculogenesis and angiogenesis in VEGF Receptor-1 Deficient Mice. Methods Mol Biol.: 161–176. https://doi.org/10.1007/978-1-4939-2917-7_12; PMid:26285753 PMCid:PMC4544766

15. Willibald Hochholzer, Tobias Reichlin, Claudia Stelzig. 2011. Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. European Heart Journal: 326–335. https://doi.org/10.1093/eurheartj/ehq429; PMid:21138939